Our Pipeline

Entrada is advancing multiple intracellular biologic programs to address devastating diseases and transform patients’ lives

Using our proprietary EEVTM  technology, we are creating a diverse pipeline of protein, peptide and oligonucleotide programs to efficiently engage intracellular disease targets

Intracellular Enzyme/Protein Replacement

Discovery
Preclinical
IND-enabling
Phase I/II
ENTR-501 for MNGIE
IC-ERT #2
Program #3

Intracellular enzyme replacement therapy (IC-ERT) is a treatment that corrects an enzyme deficiency in cells. By delivering the enzyme directly into cells, Entrada can address intracellular enzyme deficiencies in a predictable and controlled manner.

Entrada’s most advanced IC-ERT program is ENTR-501 for MNGIE (mitochondrial neurogastrointestinal encephalomyopathy), a rare, fatal mitochondrial disease caused by mutations in the gene for thymidine phosphorylase (TP). ENTR-501 consists of Entrada’s proprietary EEV linked to TP enzyme and is designed to address the deficiency of TP activity inside the cells of MNGIE patients.

Inhibition and Degradation of Intracellular Targets

Discovery
Preclinical
IND-enabling
Phase I/II
Program #1
Program #2
Program #3
Program #4

Entrada’s EEV technology delivers antibodies and peptides into cells to block pathologic protein functions common to many diseases. Additionally, Entrada’s EEV technology can be used to degrade disease-causing proteins inside cells (targeted protein degradation).

Oligonucleotide Therapeutics

Discovery
Preclinical
IND-enabling
Phase I/II
Program #1

Entrada’s EEV technology can also be used to enhance the delivery of oligonucleotides into cells. We are actively exploring several applications for this approach.